Literature DB >> 9926075

Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever.

P D White1, J M Thomas, J Amess, D H Crawford, S A Grover, H O Kangro, A W Clare.   

Abstract

BACKGROUND: The role of viruses in the aetiology of both chronic fatigue syndrome (CFS) and depressive illness is uncertain.
METHOD: A prospective cohort study of 250 primary care patients, presenting with glandular fever or an ordinary upper respiratory tract infection (URTI).
RESULTS: The incidence of an acute fatigue syndrome was 47% at onset, after glandular fever, compared with 20% with an ordinary URTI (relative risk 2.3, 95% CI 1.3-4.1). The acute fatigue syndrome lasted a median (interquartile range) of eight weeks (4-16) after glandular fever, but only three weeks (2-4) after an URTI. The prevalence of CFS was 9-22% six months after glandular fever, compared with 0-6% following an ordinary URTI, with relative risks of 2.7-5.1. The most conservative measure of the incidence of CFS was 9% after glandular fever, compared with no cases after an URTI. A conservative estimate is that glandular fever accounts for 3113 (95% CI 1698-4528) new cases of CFS per annum in England and Wales. New episodes of major depressive disorder were triggered by infection, especially the Epstein-Barr virus, but lasted a median of only three weeks. No psychiatric disorder was significantly more prevalent six months after onset than before.
CONCLUSIONS: Glandular fever is a significant risk factor for both acute and chronic fatigue syndromes. Transient new major depressive disorders occur close to onset, but are not related to any particular infection if they last more than a month.

Entities:  

Mesh:

Year:  1998        PMID: 9926075     DOI: 10.1192/bjp.173.6.475

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  44 in total

Review 1.  Chronic fatigue syndrome: probable pathogenesis and possible treatments.

Authors:  Birgitta Evengård; Nancy Klimas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review.

Authors:  Bridget Candy; Trudie Chalder; Anthony J Cleare; Simon Wessely; Peter D White; Matthew Hotopf
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

3.  Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement.

Authors:  O Zachrisson; P Colque-Navarro; C G Gottfries; B Regland; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

4.  Aetiology of fatigue in Sri Lanka and its overlap with depression.

Authors:  Harriet A Ball; Athula Sumathipala; Sisira H Siribaddana; Yulia Kovas; Nick Glozier; Peter McGuffin; Matthew Hotopf
Journal:  Br J Psychiatry       Date:  2010-08       Impact factor: 9.319

5.  Cognitive behavioural model of irritable bowel syndrome.

Authors:  Francis Creed
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

6.  Association of chronic fatigue syndrome and acute psychotic episode: is it coincidental?

Authors:  Charles Kornreich; Maya Szombat; Yun-Marie Vandriette; Bernard Dan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  Chronic fatigue syndrome after infectious mononucleosis in adolescents.

Authors:  Ben Z Katz; Yukiko Shiraishi; Cynthia J Mears; Helen J Binns; Renee Taylor
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

8.  Chronic fatigue syndrome of childhood. Comparative study with emotional disorders.

Authors:  M Elena Garralda; Luiza Rangel
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-12       Impact factor: 4.785

9.  A systematic review of chronic fatigue syndrome: don't assume it's depression.

Authors:  James P Griffith; Fahd A Zarrouf
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

10.  Chronic fatigue syndrome: identifying zebras amongst the horses.

Authors:  Samuel B Harvey; Simon Wessely
Journal:  BMC Med       Date:  2009-10-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.